Product Launch
Alkem Laboratories Becomes First Company in India to Launch Semaglutide Single-Shot Pre-Filled Syringes Starting at ₹350
NSE
alkem
BSE
539523
Alkem Laboratories has launched semaglutide in single-shot pre-filled syringe format, becoming the first company in India to offer the therapy in this delivery format. The product will be available in multiple dose strengths with prices starting at ₹350 and is intended for the management of Type 2 diabetes mellitus and obesity.
PRICE-SENSITIVE TRIGGER
Event: Launch of Semaglutide Single-Shot Pre-Filled Syringes
Type: Product Launch
Impact: Positive
Immediate Effect: The launch expands Alkem’s metabolic and chronic therapy portfolio, improves patient access to semaglutide treatment, and strengthens its positioning in the fast-growing diabetes and obesity treatment market.
Key Metrics:
- Launch Price: Starting at ₹350 per single-shot pre-filled syringe
- Product: Semaglutide
- Therapeutic Areas: Type 2 Diabetes Mellitus and Obesity
- Delivery Format: Single-shot pre-filled syringe
- Regulatory Status: DCGI approved
Highlight:
- Alkem becomes the first pharmaceutical company in India to launch semaglutide in a ready-to-use single-shot pre-filled syringe format at a starting price of ₹350.
What Happened ?
Alkem Laboratories and its subsidiaries announced the launch of semaglutide in single-shot pre-filled syringes across multiple dose strengths.
The company stated that it is the first player in India to introduce semaglutide in this format. The launch follows the company’s March 2026 introduction of semaglutide pre-filled disposable and reusable injection pens and further expands treatment options for patients suffering from Type 2 diabetes and obesity.
The company has received approval from the Drugs Controller General of India (DCGI) to manufacture and market the product in India.
Key Details
Semaglutide Portfolio Expansion:
- First company in India to launch semaglutide in single-shot pre-filled syringe format.
- Product launched in multiple dosage strengths.
- Pricing starts at ₹350, aiming to improve affordability and accessibility.
- Approved by DCGI for manufacturing and marketing in India.
- Indicated for management of Type 2 diabetes mellitus and obesity alongside diet and exercise.
- Ready-to-use syringe format improves convenience and ease of administration.
- Follows Alkem’s March 2026 launch of semaglutide disposable and reusable injection pens.
- Regulatory approval for semaglutide vial formulations has also been received, with launch planned in the future.
- Expands Alkem’s presence in chronic therapies and metabolic disorder treatment.
Note:
- The launch broadens Alkem’s semaglutide delivery ecosystem by offering patients and physicians multiple administration formats, potentially increasing treatment adoption across different patient segments.
Risk Analysis
Summary:
- While the launch strengthens Alkem’s position in the diabetes and obesity segment, commercial success will depend on physician adoption, patient acceptance, competitive pricing, and market penetration in a rapidly evolving therapeutic category.
Key Risks:
- Competition from existing and future GLP-1 therapy providers.
- Market adoption depends on physician prescribing trends.
- Pricing pressure may affect long-term profitability.
- Regulatory and reimbursement dynamics can influence uptake.
- Success depends on scaling manufacturing and distribution efficiently.
Worst Case Scenario:
- If adoption remains below expectations due to competitive intensity or pricing pressure, the new delivery format may have limited impact on market share and revenue growth.
Risk Level: Medium
Company Commentary
- Semaglutide has the potential to transform the management of metabolic disorders.
- The launch expands treatment choices available to doctors and patients.
- Multiple practical delivery formats are expected to help more patients initiate and continue therapy.
- The company remains committed to improving access to high-quality and affordable medicines.
- Alkem aims to support better patient outcomes in chronic disease management through innovative delivery options.
Official Exchange Filing: Alkem Laboratories Limited